April 1, 2013 /PRNewswire/ --
Injectable Drug Delivery M
by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] Market - Global Forecasts to 2017
,analyzes and studies the major market drivers, restraints, and opportunities in
Asia-Pacific, and Rest of the World.
- 155 market data tables
- 27 figures
- 368 pages and an in-depth Table of Content on Injectable Drug Delivery Market.
Early buyers will receive 10% customization on this report.
This report studies the global injectable drug delivery technologies market over the forecast period of 2012 to 2017.
The global injectable drug delivery market was valued at
in 2012; it is expected to reach
by 2017 at a CAGR of 14.0% from 2012 to 2017. The injectable drug delivery technologies market is broadly categorized into two major segments, namely, devices technologies and formulation technologies. Based on product, the injectable drug delivery devices technologies market is further categorized into conventional injection devices, self injection devices, and others (microneedles, nanoneedles and blunt needle injections), while injectable drug delivery formulation technologies market is categorized into conventional drug delivery formulations and novel drug delivery formulations. Conventional injection devices segment accounted for the largest share of the overall injectable drug delivery technologies market in 2012.
In addition, the market is segmented on the basis of its therapeutic applications such as auto immune diseases, hormonal imbalances, oncology, orphan/rare diseases (Hemophilia, Ribose-5-phosphate isomerase deficiency (RPI deficiency), Cystic Fibrosis, and Wilson's disease) and others (pain management, allergies, hepatitis C, and aesthetic treatment). Hormonal disorders commanded the largest share of 50.0% of the global
injectable drug delivery market
in 2012; it is expected to grow at a CAGR of 13.9% to reach
by 2017. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices. As per The American Autoimmune Related Diseases Association, 50 million Americans or 20% of the population or one in five people, are living and managing with auto immune diseases during the year 2013.
The major geographic markets covered in this report are
, and Row.
dominates the market, followed by
. However, Asian and Latin American countries represent the fastest growing markets due to growing number of cancer and diabetes incidences, and improving patent compliance.
The key players in this market are
& Co. (U.S.), Baxter International, Inc. (U.S.), SHL Group (
), Ypsomed Holding AG (
), Terumo Corporation (
), Owen Mumford Ltd (U.K.), and Antares Pharma, Inc. (U.S.).
Buy a copy of this report @